Reconnaissance for Intraperitoneal Immunotherapy

Peritoneal metastasis (PM) is a commonly encountered and dreaded complication of abdominal malignancy. Traditionally, it was approached with therapeutic nihilism and palliative measures, most commonly systemic chemotherapy. However, more aggressive approaches to PM have become mainstream therapy for selected patients. Cytoreductive surgery (CRS) and, potentially, intraperitoneal adjuvants such as hyperthermic intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC), and others have been found to improve outcome and quality of life. CRS, combined with appropriate systemic therapy, offers outcomes only dreamed of just a few decades ago. Despite this improvement, many patients will still succumb to their disease, and new approaches are desperately needed. …